Search

Displaying results 4741 - 4750 of 5040 in total
  1. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron has a monoisotopic molecular weight of 574.2 Da.

  2. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

  3. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    Icalcaprant has a monoisotopic molecular weight of 406.2 Da.

  4. Drug

    Atirmociclib

    go.drugbank.com/drugs/DB21733
    Investigational

    Atirmociclib has a monoisotopic molecular weight of 463.18 Da.

  5. Drug

    Plosaracetam

    go.drugbank.com/drugs/DB21594
    Investigational

    Plosaracetam has a monoisotopic molecular weight of 330.05 Da.

  6. Drug

    Olomorasib

    go.drugbank.com/drugs/DB21697
    Investigational

    Olomorasib has a monoisotopic molecular weight of 528.08 Da.

  7. Drug

    Istisociclib

    go.drugbank.com/drugs/DB21703
    Investigational

    Istisociclib has a monoisotopic molecular weight of 287.21 Da.

  8. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  9. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB17997
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  10. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes